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Abstract
Background: Phenotypic alteration of vascular smooth muscle cells (SMC) in response to injury or inflammation is an
essential component of vascular disease. Evidence suggests that this process is dependent on epigenetic regulatory
processes. P300, a histone acetyltransferase (HAT), activates crucial muscle-specific promoters in terminal (non-SMC)
myocyte differentiation, and may be essential to SMC modulation as well.
Results: We performed a subanalysis examining transcriptional time-course microarray data obtained using the A404 model
of SMC differentiation. Numerous chromatin remodeling genes (up to 62% of such genes on our array platform) showed
significant regulation during differentiation. Members of several chromatin-remodeling families demonstrated involvement,
including factors instrumental in histone modification, chromatin assembly-disassembly and DNA silencing, suggesting
complex, multi-level systemic epigenetic regulation. Further, trichostatin A, a histone deacetylase inhibitor, accelerated
expression of SMC differentiation markers in this model. Ontology analysis indicated a high degree of p300 involvement in
SMC differentiation, with 60.7% of the known p300 interactome showing significant expression changes. Knockdown of
p300 expression accelerated SMC differentiation in A404 cells and human SMCs, while inhibition of p300 HAT activity
blunted SMC differentiation. The results suggest a central but complex role for p300 in SMC phenotypic modulation.
Conclusions: Our results support the hypothesis that chromatin remodeling is important for SMC phenotypic switching,
and detail wide-ranging involvement of several epigenetic modification families. Additionally, the transcriptional coactivator
p300 may be partially degraded during SMC differentiation, leaving an activated subpopulation with increased HAT activity
and SMC differentiation-gene specificity.
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Introduction
The ability of mature vascular smooth muscle cells (SMC) to
modulate their phenotype is responsible in large part for many of
the specific manifestations and genesis of vascular diseases such as
hypertension, atherosclerosis, and post-angioplasty restenosis
[1,2,3]. Unlike skeletal and cardiac myocytes, vascular SMCs
respond to environmental cues by de-differentiating: down-
regulating SMC marker and contractile proteins (e.g. smooth
muscle [SM] a-actin, transgelin, SM-myosin heavy chain [MHC]),
migrating into the neointima, proliferating, and secreting matrix
and remodeling factors.
The molecular mechanisms underlying lineage determination
and terminal differentiation of these cells have received much
attention, but the genetic programs that regulate these processes
have not been fully defined. Experiments have identified levels of
epigenetic regulation underlying SMC plasticity, including specific
histone modifications that appear to support the SMC lineage and
alter the ability of the transcriptional regulator serum response
factor (SRF) to target SMC marker-gene promoters [4,5].
DNA in eukaryotic nuclei is packaged into repeating units of
chromatin, composed of nucleosomes, with 145–147 DNA base
pairs wrapped around an octameric core containing two molecules
each of histones H2A, H2B, H3 and H4. The core is then
stabilized into higher order structures by linker histone H1 [6,7,8].
The amino-terminal portions of core histones contain flexible
protease-sensitive tails which are evolutionarily conserved sites for
post-translational modifications, including methylation, acetyla-
tion, phosphorylation, ubiquitylation, and ADP-ribosylation [9,10,
11]. These modifications are correlated with replication, chroma-
tin assembly, and transcription [7,12]. In general, acetylation of
histones is transcriptionally activating, while mono-, di- and tri-
methylation may cause silencing or activation depending on which
particular lysine residues are modified.
Various enzymes and enzymatic complexes (e.g. histone
acetyltransferases (HATs), histone deacetylases (HDACs), histone
and DNA methyltransferases (HMTs and DNMTs) regulate
transcription through chromatin modification, partly through a
‘‘histone code’’ in which combinations of specific residue modifi-
cations regulate unique biological outcomes [13]. Numerous
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‘‘read’’ the code and recruit transcription factors or repressors.
HATs are well characterized covalent histone modification
systems, and consist of several protein families including CBP/
p300 [7]. CBP and p300 are paralogues, and act as multifunc-
tional transcriptional co-activators involved in such varied
processes as embryonic development, differentiation, proliferation
and apoptosis [14]. Expressed ubiquitously during mouse
development, they interact with numerous transcription factors,
integrating complex signal transduction pathways at the level of
gene transcription. CBP and p300 are necessary factors in skeletal
myogenesis and cardiomyogenesis [15–19]. Several studies have
indicated that p300 may be necessary for SMC differentiation, and
is likely also essential for phenotypic switching [4,20–25].
The P19-derived A404 embryonal cell line differentiates toward
the SMC lineage in the presence of retinoic acid (RA), and allows
selection for cells adopting a SMC fate through a differentiation-
specific drug marker (puromycin) [20]. We previously performed
expression profiling of differentiating A404 cells, and identified
numerous ontology-based pathways that undergo differential regu-
lation [26]. Among the most prominent pathways identified was
chromatin remodeling. We sought to further characterize the role of
chromatin remodeling and p300 in SMC differentiation. Results
support the hypothesis that chromatin remodeling factors, and p300
in particular, are important for SMC phenotypic switching.
Methods
Cell culture, RNA isolation
The A404 cell culture protocols, microarray hybridization, and
RNA isolation methods were previously published [26]. Briefly,
undifferentiated P19-A404 cells (Control) were treated with
1 mmol/L all-trans retinoic acid (RA) for 24 hours (RA24),
48 hours (RA48), 96 hours (RA96), or 96 hours followed by
puromycin (Puro). RNA was harvested from multiple replicates at
each of the four time points, isolated by chloroform extraction
followed by Qiagen RNeasy Midi Kit Protocol, and quantitated by
Nanodrop (Agilent Technologies, Santa Clara, CA).
Human coronary SMCs (Clonetics, Lonza Group Ltd.,
Switzerland) between passages 3 and 6 were propagated in
SMGM – growth medium (Clonetics) to 85% confluence (subset
harvested as control) and then placed in serum-free SMBM – basal
medium (Clonetics) for either 48 or 72 hours, with a minimum of
three plates per sample per time point. Cells were then harvested
for protein or RNA isolation as described.
HDAC inhibition with trichostatin A
Culture protocols were identical to those used previously, except
that A404 cells were treated instead for 48 hours with vehicle -
diluted 100% ethanol (Control), with 10 ng/mL of trichostatin A
(TSA) (Sigma, St. Louis, MO), with vehicle +1 mmol/L all-trans
retinoic acid (RA) (Sigma), or with trichostatin and retinoic acid
(TSA/RA). Protocol was derived from Minucci, et al [27]. Multiple
replicates and multiple plates/replicate were utilized. RNA was
harvested, isolated, and quantitated as above. A separate set of
replicates were treated identically, but instead harvested for histone
extraction using established methodology (below) [28].
Chemical p300 HAT inhibition
Lys-CoA-TAT, a cell-permeable chemical inhibitor of p300
HAT, was the kind gift of Philip A. Cole and colleagues at Johns
Hopkins [29]. A404 cells (6 RA and 6TSA) were treated for 24 or
48 hours with 20 mM Lys-CoA-TAT, using an empty TAT-peptide
as a control. They were then harvested at time 0, and at 48 h for
RNA or 24 h for protein. All medium was replenished at 24 hours.
All treatment wells were .90% confluent at time of harvest.
siRNA knockdown of EP300/Ep300
Cultured human SMC and A404 cells were transfected with
Silencer Select siRNAs targeting either EP300 or Ep300
transcripts as appropriate, as well as GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) as a positive control, and scrambled
negative control siRNA (Applied Biosystems). Forward transfec-
tion was performed in 6-well plates using 3 mL/well of
Lipofectamine RNAiMAX (Invitrogen) per recommended proto-
col, using 10 nM (30 pmol) siRNA, when cells were 40–50%
confluent. Three replicates per condition were included. Human
SMCs were serum starved for 48 hours, beginning 24 hours after
transfection. A404 cells were treated with DMSO vehicle or
1 mmol/L all-trans retinoic acid (RA) for 24 or 48 hours, starting
5 hours post-transfection. Cells were then harvested for RNA.
Histone and total protein isolation
For the HDAC inhibition studies, cells were collected, washed with
ice-cold PBS, and centrifuged for 5 minutes at 6006g. The pellet was
re-suspended in ice-cold lysis buffer, centrifuged, and washed with
10 mM Tris-HCl, 13 mM EDTA. After spinning again, the pellet
was re-suspended in 0.4 N H2SO4 and acid extracted on ice for
1 hour. Centrifugation at 10,0006g was followed by acetone
precipitation at 220uC for 1 hour, and centrifuging at 10,0006g.
The histone pellet was air-dried, re-suspended in water and stored at
280uC. For some studies, histones were isolated using the Active
Motif Histone Purification Mini Kit (Carlsbad, CA) per manufac-
turer’s protocol. Protein was quantitated by either Thermo Scientific
BCA Protein Assay Kit (Rockford, Ill) or Bio-Rad DC Protein Assay
(Hercules, CA) with a bovine serum albumin standard (R
2=0.999).
Isolation of total protein for p300 immunoblotting was
performed by rinsing with ice-cold PBS, lysing the cells with
CelLytic-M (Sigma) containing protease inhibitor cocktail (Sigma),
spinning at 15,0006g for 15 min and collecting the supernatant.
Protein was quantitated by DC protein assay.
Western blots
Western immunoblotting of HDAC inhibition samples was
performed using 1–4 mg/lane protein in Tris-Glycine SDS Sample
Buffer (Invitrogen, Carlsbad, CA) loaded onto 12% or 15% SDS-
PAGE gels. Gapdh was used as a loading control. Protein was
transferred to PVDF (polyvinylidene fluoride) membranes, blocked
with 3% PBS-milk (Upstate Cell Signaling Solutions, Waltham,
MA), and probed with 1 mg/mL rabbit anti-acetyl histone H4 or
0.5–1.0 mg/mL anti-histone H4 (Upstate) followed by 0.2 ng/mL
goat anti-rabbit horseradish-peroxidase-conjugated IgG, and de-
veloped with Visualizer Working Solution (Upstate). Membranes
were exposed using BioMax MS Film (Kodak, Rochester, NY).
Western blots of human coronary SMC and A404 p300 utilized
1 mg/mL rabbit anti-p300 (N-15, Santa Cruz Biotechnology, Inc,
Santa Cruz CA). Samples were diluted in NuPAGE LDS 46
Sample Buffer (Invitrogen) and loaded onto NuPAGE Novex 3–
8% Tris-Acetate gels with SeeBlue Plus2 Ladder for size
calibration. Other processing was similar to that described above.
Exposed films were scanned, and integrated band densities were
obtained and normalized to Gapdh and background using ImageJ
[30]. Mean 6 std dev of lane duplicates are shown in density units.
Quantitative reverse-transcription PCR
Total RNA was converted to cDNA using MMLV reverse
transcriptase. The cDNA was amplified in triplicate on the ABI
SMC Chromatin and p300
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Biosystems, Foster City, CA). Gene expression levels were
normalized to corresponding 18S internal controls. At least two
representative samples from each time point were evaluated. Fold
changes were calculated by the method of DDCt.
Data analysis
Microarray methods have been previously described [26]. All
microarray data were submitted to the Gene Expression Omnibus
(GEO) database at the NCBI (GSE1506;http://www.ncbi.nlm.nih.
gov/geo/). Array data were probed using GOMiner [31] and the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) [32] to identify all genes annotated with ontology terms
related to chromatin remodeling and assembly, gene silencing, or
histone modification. These were then cross-referenced against
genes showing significant regulation (false discovery rate - FDR,1)
during A404 SMC differentiation. Relative overabundance calcu-
lations were performed using Fisher’s Exact Test. Heatmaps were
created using Heatmap Builder 1.0 (Ashley E., Spin J., Watt C.,
Stanford) [26]. Two-tailed unpaired t-tests were used to evaluate
significance for qRT-PCR results.
The p300-transcription factor interactome was derived with
PathwayAssist 3.0 (Ariadne Genomics, Inc., Rockville, MD),
which utilizes KEGG, DIP, and BIND databases and natural
language scans of PubMed to define connectivity among genes to
delineate a functionally related network.
Results
Chromatin remodeling genes show widespread
regulation with in vitro SMC differentiation
In previously published work, A404 P19 mouse embryonal
carcinoma cells were induced to differentiate into SMCs using all-
trans retinoic acid (RA) treatment for 96 hours, followed by
Figure 1. Heatmap and regulated chromatin remodeling genes. Left: Row-normalized gene expression heatmap of A404 cells treated with
all-trans retinoic acid for 96 hours, then puromycin for 48 hours, significant at FDR,1. Shown are 2,739 genes upregulated (P.C), and 2,227 genes
downregulated (C.P). C=Control replicates, n=6. P=Puromycin group replicates, n=6. Green: down. Red: up. One gene/row. Right: Regulated
chromatin remodeling genes during A404 differentiation. GO annotation terms for selected pairwise SAM comparisons (FDR,1) of treatment groups
were obtained, using gene lists with unique names. Values are % of total set of 171 chromatin remodeling genes on array. Downregulated and
Upregulated = vs. control A404 cells. RA48 and RA96 = RA-treated for 48 or 96 h. Puro = RA-treated 96 h, then puromycin-treated for 48 h.
doi:10.1371/journal.pone.0014301.g001
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SM a-actin), and then RNA-harvested for microarray transcrip-
tional profiling [26]. We used a 60-mer microarray platform
(Agilent, Palo Alto, CA) with 20,280 mouse transcripts derived from
the National Institute on Aging clone set, and identified 2,739 genes
that were significantly upregulated from untreated cells after
differentiation was completed (FDR,1), as well as 2,227 downreg-
ulated genes. Temporal patterns of regulation were also identified.
In an updated analysis, ontologic pathways within these data were
scrutinized using GOMiner and DAVID. The array was found to
contain 171 unique genes related to chromatin remodeling, including
such aspects as histone tagging (acetylation, deacetylation, methyla-
tion), chromatin assembly/disassembly, and silencing. A substantial
percentage of these genes showed significant regulation (FDR,1)
during SMC differentiation, with more downward regulation than
upward overall (Figure 1). The smallest changes were seen early in
differentiation (8.2% down and 9.4% up at 48 hours of RA), while
the largest response occurred in the mid-portion of the time-course
(42.1%downand20.5%up incellstreated 96 hwithRAvs.control).
After using puromycin, 32.7% and 18.7% of chromatin remodeling
genes remained down- and upregulated respectively.
Pathway analysis of chromatin remodeling genes during
SMC differentiation shows diverse response
Seeing the extent of chromatin-related gene regulation, we next
inspected the specific biological/molecular pathways within the
set, and found a variety of patterns within individual gene classes.
One highly represented class included proteins that silence
chromatin via DNA methylation (Figure 2a), and included
chromobox genes, members of the DNMT protein family, as well
as methyl-CpG binding domain (MBD) family genes.
Another well-represented class included histone methyltransfer-
ases (HMTs). Generally speaking, methylated histones bind DNA
more tightly, which inhibits transcription (Figure 2b).
Several known HAT genes displayed significant regulation
(Figure 2c) during SMC differentiation. Some were downregu-
lated, including Ncoa3, Hat1, CBP/Crebbp, and Pcaf. In contrast,
Myst3 was upregulated by 96 h and remained so. While p300/
Ep300 was not on the array, qRT-PCR Taqman studies showed
minor gene upregulation with A404 differentiation over control:
mean 1.2-fold (24 h, RA), 1.6-fold (48 h RA), and 1.3-fold (96 h,
RA). Although p300 transcription changes were small, it should be
noted that numerous signaling pathways are known to post-
transcriptionally regulate its protein activity.
A number of regulated genes contained SWI/SNF protein
subunits, which are involved in chromatin assembly and
Table 1. HDAC expression with SMC differentiation.
Probe Retinoic Acid-96 hours Puromycin











Fold changes vs. control for histone deacetylase genes and SMC marker genes
during A404 differentiation time-course. NS: not significant. For significant
changes, FDR,1.
doi:10.1371/journal.pone.0014301.t001
Figure 2. Differential regulation of selected chromatin remod-
eling gene classes with SMC differentiation. A. DNA methyltrans-
ferases. B. Histone methyltransferases. C. Histone acetyltransferases. D.
SWI/SNF family. Row-normalized heatmaps are shown labeled with
gene symbols. Control = untreated A404 cells. RA48/RA96 = Retinoic
acid treated for 48 and 96 h respectively. Puro = Treated with RA for
96 hours, then puromycin for 48 hours. Green: down. Red: up.
doi:10.1371/journal.pone.0014301.g002
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activity. Nearly all of these genes were decreased during the
treatment course (Figure 2d). Smarcal1, Smarcb1, Smarcc1,
Smarcd1, and Smarcd3, and Smarcf1 all showed significant
downregulation by 96 h of RA treatment and remained so.
However, Smarca5 was strongly upregulated early. Transcription
then tapered downward, but remained significantly increased
throughout.
A404 SMC differentiation was also accompanied by highly
variable regulation of histone deacetylases (Table 1). Two Class I
HDACs, Hdac2 and 3, showed minimal to no significant change
until the final selection step with puromycin, and then moved in
opposite directions. Hdac1, in contrast, was downregulated by
96 h of RA-treatment and remained so. The Class II HDACs,
which are thought to be more tissue specific, displayed
dramatically different responses from each other. For example,
Hdac6 was downregulated 50-fold by 96 h, while Hdac7a and
Hdac9 both showed significant upregulation. Notably, Class III
HDAC Sirtuin 1 (Sirt1), a protein- and histone-deacetylase known
for inhibiting differentiation of skeletal muscle via its involvement
in Pcaf and p300 suppression [33,34], showed early and persistent
downregulation throughout. Another member of the same family,
Sirt3, was also significantly downregulated at 96 h.
HDAC inhibition accelerates rate of SMC marker gene
increase with differentiation
Given the varying regulation of various HDAC family
members, we investigated the effect of HDAC suppression using
Trichostatin A (TSA) during RA-induced SMC differentiation.
Immunoblotting revealed some baseline histone H4 acetylation
present in proliferating, untreated A404 cells (Figure 3a).
Treatment with TSA and RA together led to greatly increased
levels of acetyl-histone H4 compared with RA alone or untreated
control, verifying that TSA at this concentration inhibits histone
deacetylation in the A404 model. Control H4 histone levels did
not alter significantly with RA treatment, with time, or with the
addition of TSA.
As expected, treatment with retinoic acid significantly increased
expression of the SMC markers SM a-actin (Acta2), transgelin/
SM22a (Tagln), and caldesmon 1 (Cald1) markers at 48 hours
relative to vehicle-treated cells: 22.0-fold, 3.2-fold, and 4.1-fold
respectively (FDR,1, microarray). However, treatment with TSA
combined with RA further increased expression for all three
Figure 4. p300 interactome transcription factors. Transcription
factors in the p300 interactome which demonstrated significant
regulation during A404 differentiation vs. untreated cells (FDR,1).
White = unchanged. Light grey = upregulated. Dark grey =
downregulated. Gene number and % of interactome shown for each
section.
doi:10.1371/journal.pone.0014301.g004
Figure 3. Trichostatin A and SMC differentiation markers. A. Western blots of A404 cell histone extract, using anti-acetyl histone H4 or anti-
histone H4 primary antibody. Cntrl = Control; RA = retinoic acid; TSA/RA = trichostatin A+ retinoic acid. Time 0 and 48 h of treatment are shown.
B. Increased relative expression of SMC differentiation markers after 48 h in TSA + RA-treated A404 cells vs. RA-treated alone. For all ratios, p,0.05.
Acta2 = SM a-actin, Tagln = transgelin/SM22a, Cald1 = caldesmon 1.
doi:10.1371/journal.pone.0014301.g003
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Ratios of TSA-RA-treated expression to RA-treated were 9.1-fold
(Acta2), 1.4-fold (Tagln), and 2.3-fold (Cald1).
SMC differentiation is accompanied by widespread
regulation of the p300 transcription factor-interactome
P300/Ep300 is believed to be an important regulator of smooth
muscle-specific gene expression, and is a known key player in
epigenetic regulation during skeletal and cardiac myocyte
differentiation. PathwayAssist, a literature-based program for
mapping molecular relationships, was used to identify all
transcription factors known to interact directly with p300/
Ep300. This yielded a total of 162 genes, of which 130 were on
the array (Figure 4). During SMC differentiation of A404 cells,
72 (55.4%) of these genes showed significant differential
regulation, pathway over-representation that was highly significant
by Fisher’s Exact Test (p,0.0001). From this set, 42 (58.3%) were
up and 30 (41.7%) were down. This supports the idea that p300
Figure 5. p300 protein levels with SMC differentiation/serum-starvation. Plots of scanned, digitized Western blots probed with anti-p300,
and representative blots. A. Top: A404 cells treated with retinoic acid for up to 96 hours. Bottom: A404 p300 Western blot. Two lanes per time point,
same order as plot. B. Top: primary human coronary artery SMCs, serum starved for up to 72 hours. Bottom: CASMC p300 Western blot. Two lanes per
time point, same order as plot. Integrated band densities were normalized to Gapdh and background. Mean 6 standard deviation of lane duplicates
are shown in density units.
doi:10.1371/journal.pone.0014301.g005
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the precise nature of its involvement.
P300 protein levels decrease with SMC differentiation
Having established that minimal transcriptional regulation of
p300 accompanies SMC differentiation, but that the majority of
the p300 interactome shows significant change, we next used
Western blotting to examine p300 protein levels. P300 protein
levels decreased dramatically during the 96 hour retinoic acid
time-course (Figure 5a). Nearly all of this change occurred within
the first 48 h of treatment.
We sought to confirm this finding in another model of SMC
differentiation. Primary vascular smooth muscle cells rapidly de-
differentiate in vitro, a process that partially reverses under
conditions of serum-starvation [2]. Human coronary smooth
muscle cells were serum starved in basal medium for 48 and
72 hours and then harvested for RNA or protein. Taqman qRT-
PCR showed the expected increases in ACTA2 and MYH11 (SM-
MHC) with starvation, while p300 showed similar regulation to
A404 differentiation (a mild 1.4-fold increase) (Figure 6). Western
blotting results paralleled those in A404 cells, with p300 levels
decreasing substantially during the time course (Figure 5b).
Direct chemical inhibition of p300 histone
acetyltransferase activity blunts SMC differentiation
Because p300 possesses other functions beyond acetyltransferase
activity, we sought to confirm that p300’s HAT activity is
important in SMC differentiation. Several small molecule
chemical inhibitors have been developed which act as bisubstrate
analogs [35,36,37]. A potent and selective cell-permeable inhibitor
of p300 HAT activity, Lys-CoA-TAT, was previously developed
by Philip A. Cole and colleagues[29].
A404 cells (6 retinoic acid) were treated over 24 or 48 hours with
20 mM Lys-CoA-TAT, using an empty TAT-peptide as a control.
Neither Lys-CoA-TAT nor TAT-peptide alone had any significant
impact on A404 cell expression of SMC markers by qRT-PCR.
(Figure 7). At both time points Lys-CoA-TAT treatment
significantly (p,0.05) decreased the effects of retinoic acid on
SMC marker expression (Figure 8). Suppression was 46.9% for
Acta2 and 28.0% for Tagln at 24 hours. Further, co-incubation of
A404 cells with TSA, RA and Lys-CoA-TAT (Figure 9) confirmed
that the HAT inhibitor was effective at the dose used, as it
successfully blunted the increase in TSA-induced histone H4
acetylation seen with RA-induced SMC differentiation by 43%.
Knockdown of p300 with siRNA accelerates SMC
differentiation
Since p300 protein levels decreased during SMC differentiation,
we also investigated the impact of EP300/Ep300 knockdown using
siRNA in both the human SMC and A404 models. The
transfection protocol used produced an average 95.4% reduction
in expression of the GAPDH positive control. In human SMCs,
EP300 expression was decreased 66.8% in serum-fed cells and
75.7% in cells serum-starved for 48 h (p,0.05 for both vs.
negative control siRNA). A404 cells also demonstrated significant
knockdown: 66.3% in untreated cells, 57.6% in 24 h RA-treated
cells, and 70.1% at 48 h of RA-treatment (p,0.05 for all vs.
negative control siRNA).
Serum-starvation in human SMCs transfected with negative
control siRNA led to the expected increases in ACTA2 and
MYH11 expression. However, cells transfected with siEP300
showed significantly higher expression of both markers after
48 hours of serum-starvation (p,0.05) (Figure 10a).
A404 cells displayed similar behavior, with expression levels of
SMC differentiation markers Acta2, Myh11 and Tagln incremen-
tally increasing with RA-treatment over time, despite transfection
with negative control siRNA. As seen in previous studies, rises in
Acta2 and Tagln were already significant at 24 hours, while the
increase in Myh11 was delayed. As with the human SMCs, marker
expression levels increased significantly beyond negative control
siRNA-transfected samples by 48 hours of RA-treatment (p,0.05
for all) (Figure 10b).
Figure 6. Gene regulation in human coronary SMCs by qRT-PCR. Cells were serum starved in basal medium for up to 72 h to induce
differentiation. P300 = EP300 HAT, ACTA2 = SM a-actin, MYH11 = SM-MHC. 48 and 72 h time points are shown as fold change from baseline 6
standard error. All values are significantly increased vs. control (p,0.05).
doi:10.1371/journal.pone.0014301.g006
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Epigenetic regulation is a key determinant of SMC
phenotypic state
SMC phenotypic change is a varied and complex process.
Evidence has been steadily accruing that epigenetic regulation is a
vital element in the determination of SMC differentiation state,
particularly in the areas of histone acetylation and methylation.
Just as critical to SMC plasticity is the removal of inhibitory/
chromatin compacting complexes from SMC-marker gene
promoters, such as certain HDACs and other factors such as
Klf4 [4]. These mechanisms already have established involvement
in skeletal and cardiac muscle differentiation and hypertrophy
[15,38]. Further, it is necessary for SMC differentiation that SRF
(a ubiquitous protein capable of activating transcription for many
gene subclasses) be specifically denied to growth and proliferation
genes, and that those genes remain silenced while the cells are
quiescent.
Various histone methyl-lysine patterns are able to distinguish
SMCs from non-SMCs [5]. Recruitment of SRF, and in particular
the activating SRF/myocardin complex, to conserved CArG
boxes in SMC-specific gene promoters has been associated with
acetylated H3 and H4, dimethylated H3K4, and methylated
H3K79 [4,20–23]. A study from Lockman et al. found that a
histone demethylase (Jmjda1) bound all three myocardin family
members, and when overexpressed in 10T1/2 cells decreased
mono- and di-methyl H3K9 while stimulating the transgelin and
SM a-actin promoters [39].
Major chromatin remodeling families undergo regulation
with SMC differentiation
This study demonstrates that widespread regulation of chroma-
tin modifying and remodeling genes takes place during SMC
differentiation in vitro. At the maximum level observed (96 h of
retinoic acid treatment), over 60% of all chromatin remodeling
genes identified on the array showed significant changes in
transcription from control, dramatically increasing in the second
48 h of treatment (from 17.6%). While numbers of positively and
negatively regulated genes started at similar levels, by far the
majority of this increase was driven by downregulated genes. As
would be expected with such sweeping changes in expression,
numerous classes of epigenetic regulators were represented,
including DNA methyltransferases, histone methyltransferases,
and others. A few highlights are presented below.
Figure 7. p300 HAT inhibition controls. A404 cells were treated for 24 hours with: 1) retinoic acid (RA), 2) 20 mM Lys-CoA-TAT (LysCoAT),
or 3) 20 mM control TAT peptide (TAT). Expression levels obtained by qRT-PCR for SMC markers are shown as fold change from baseline untreated
cells 6 standard error. * = significantly (p,0.05) different from control.
doi:10.1371/journal.pone.0014301.g007
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homologs Cbx1 and Cbx3. The products of these genes (HP1beta
and HP1gamma) recognize tri-methylated H3K9 and mediate
silencing through conversion to heterochromatin [40,41]. Lock-
man et al. suggests that H3K9 demethylation at SMC-marker
gene promoters may trigger conversion to euchromatin [39].
Prmt1 acts as an H4R3 arginine methyltransferase, a modifica-
tion which facilitates p300-mediated histone acetylation [42], and
showed mild down-regulation. A homologous gene, Prmt2, binds to
the retinoic acid receptors RARa and RXRa [43,44]. It interacts
with a HAT, steroid receptor coactivator 1 (SRC-1), and might
relate to RA-mediating triggering of A404 differentiation, as it is
upregulated at the earliest time point and then remains unchanged.
Vire et al. [45] showed that the silencing pathways of the
Polycomb group and DNA methyltransferase systems are
mechanically linked. Our data imply that relief from Dnmt3a-
and Dnmt3b-associated DNA methylation may be essential to
preventing HDAC recruitment to SMC-specific genes during
differentiation via methyl-CpG-binding proteins such as Mecp2
and Mbd2. Somewhat surprisingly, these latter two genes showed
upregulation in our model, possibly reflecting a compensatory
response to DNMT repression or increased protein degradation,
or a redirecting of the silencing machinery toward growth and
proliferation genes that could be targeted by Dnmt1 and Dnmt2
(both upregulated late in this study).
HDAC inhibition promotes SMC differentiation: seeking
the key regulators
Histone deacetylases are divided into three classes. Class I
HDACs (1–3, 8) are similar to yeast RPD3 and localize to the
nucleus. Class II HDACs (4–7, 9–10) resemble yeast HDA1 and
are found in both nucleus and cytoplasm, while Class III HDACs
are NAD-dependent enzymes similar to yeast SIR2 proteins [46].
These proteins inhibit transcription through removal of key acetyl
groups. In addition to their effects on histones, some HDACs are
also believed to exert effects in the cytosol through protein
deacetylation. For example, HDAC8 reportedly associates with
the smooth muscle actin cytoskeleton and may regulate the
contractile capacity of smooth muscle cells [47].
Relief from Class II HDAC inhibition is necessary for
differentiation of both skeletal and cardiac myocytes, and evidence
exists for a similar role in SMCs [48]. Global HDAC suppression
with trichostatin A inhibits SMC proliferation, accelerates
differentiation in P19 cells, and stimulates acetylation at the
transgelin locus in fibroblasts [21,27,49]. Qiu et al. overexpressed
Figure 8. p300 HAT inhibition and A404 SMC differentiation markers. A404 cells were treated for 24 or 48 hours with retinoic acid (RA)
620 mM Lys-CoA-TAT. Shown are qRT-PCR expression values for Acta2 and Tagln, calculated as a percent of the RA-induced marker level for that time
point. An RA-treatment bar is shown for comparison. * = significantly (p,0.05) different from cells treated with RA alone.
doi:10.1371/journal.pone.0014301.g008
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of transgelin by Smad3 and myocardin in their cell systems [50].
Another study, however, showed that Class II HDACs 4 and 5
suppressed the ability of myocardin to activate SM a-actin and
transgelin, while Class I HDACs 1 and 3 had no effect [23].
Notably, they also observed that A7r5 SMCs expressed HDACs1–
2, and 4–7, but not HDAC3 or 9.
We found that A404 cells, in contrast, expressed both Hdac3 and
9. However, Hdac3 was suppressed with differentiation while Hdac9
showed progressive upregulation over time. Hdac6 essentially
disappeared with SMC differentiation. Loss of marker expression
SMCs in Klf4 over-expression assays has been associated with the
appearance of the H4 deacetylase HDAC2 [4], but in A404 cells
Hdac2 showed minimal change in expression during differentiation.
Differences between the various experimental models might explain
some of these results. We did identify a notable drop in Hdac5
transcription with advancing differentiation, consistent with relief of
suppression of myocardin. Further, we showed that inhibition of
HDACs with trichostatin A accelerated A404 SMC differentiation.
It remains to be established which HDACs play exactly which roles
in regulating SMC plasticity.
HAT activity of p300 plays a key role in SMC
differentiation: evidence for an activated subpopulation
Previous research has offered hints that acetylation of SMC-
specific promoter loci is crucial for differentiation, and evidence
suggests that p300 is involved in accomplishing this [20]. Studies
have identified acetyl-H3K9, -H3K14 and -H4 as distinguishing
marks in SMCs (vs. non-SMCs), although it is notable that while
myocardin increased acetylation of H3K9 it did not increase
H4Ac, implying a separate activation step [4]. Myocardin requires
SRF to activate SMC genes, and SRF has been reported to
associate with the p300-related HAT CBP during c-Fos activation
[51], however p300 is able to enhance myocardin independently
of SRF association [23]. Further, p300 interacts with the SMC
differentiation-promoting transcription factor GATA6, and the
combination activates the SM-MHC promoter [24]. The ability of
myocardin to activate SMC genes is enhanced by p300, which
binds to its transcriptional activation domain in a separate location
from HDAC5 [23].
The paralogues CBP and p300 are present in limiting amounts
in mammalian cells, and signaling pathways may regulate
transcription based on their ability to compete for these factors
[52–55]. While CBP and p300 are known as HATs they may also
act as transcriptional co-factors, and additionally may regulate via
acetylation of non-histone proteins [14]. Numerous signaling
pathways utilize these factors. Using PathwayAssist we identified
162 different proteins which have been shown to interact with
p300, of which 130 were present on our microarray. In concert
with the large scale transcriptional regulation of chromatin
remodeling genes which occurred during the A404 time course,
over half of the available p300 interactome showed significant
changes. It therefore seems highly probable that global alterations
in p300-based signaling accompany SMC differentiation.
Figure 9. p300 HAT inhibition and trichostatin A. Area-under-the-curve (AUC) pixel densitometry was calculated for scanned, digitized anti-
acetyl-histone H4 Western blots (shown at bottom) of A404 cells either untreated (Cntrl), or treated with trichostatin A+ retinoic acid (RA/TSA) or
trichostatin A+ retinoic acid + Lys-CoA-TAT (LysCoA/RA/TSA) for 24 hours. Values shown are a ratio of anti-acetyl-histone H4:anti-histone H4,
normalized to untreated control AUC 6 standard error for three experiments. Western lanes (in duplicate) correspond to graph columns.
doi:10.1371/journal.pone.0014301.g009
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essential for SMC differentiation, although histone acetylation and
co-activation of myocardin are supported by the evidence
presented above. Our experiments show that direct chemical
inhibition of p300 HAT activity substantially decreases (but does
not completely arrest) SMC differentiation. Histone acetylation of
H3K9, H4, and H3K14 may therefore be attributable to p300.
However, interactions between p300 and myocardin might occur
independently of acetyltransferase activity.
Further, alternative HATs might also be involved. While several
HATs (including CBP) showed significant downregulation with
SMC differentiation (Figure 2), Myst3 showed progressive
upregulation throughout. Little is known about this factor at this
time apart from its involvement in monocytic leukemia and
hematopoietic stem cells [56]. Additionally the HAT PCAF was
likely partially inhibited by the concentration of Lys-CoA-TAT that
we employed, making our results not completely p300-specific.
Several studies have indicated that activity of CBP and p300 may
depend on their phosphorylation state and be regulated by retinoic
acid receptors, and that signaling may trigger the formation of an
activated p300 subpopulation with increased differentiation-gene
specificity [54,57–61]. During retinoic acid-induced differentiation
of F9 cells, p300 (but not CBP) protein levels decreased during
differentiation due to increased degradation by the ubiquitin-
proteasome pathway. This was accompanied by a significant
increase in per molecule HAT activity, and specifically with protein
kinase A-mediated phosphorylation of p300 [61].
We examined this process in A404 SMC differentiation and
observed similar behavior. After treatment with retinoic acid, p300
protein levels in A404 cells progressively decreased despite only
minimal changes in p300 transcription, with most of the change
occurring early. The same was observed in a model of human
SMC re-differentiation. Further, siRNA knockdown of p300
expression in both models accelerated SMC differentiation,
suggesting that the observed decrease in p300 levels may trigger
SMC differentiation.
As mentioned above, p300 is central to numerous transcrip-
tional activation pathways, including those of proliferation and
growth, and is present in limiting amounts among competing
signaling processes. Thus, in SMCs undergoing differentiation, a
decrease in p300 protein levels accompanied by activating
covalent modifications could cause migration of the factor from
Figure 10. p300 siRNA knockdown and human SMC differentiation markers. A. Human CASMC were transfected with either scrambled
negative control siRNA (siNeg) or with a transcript targeting EP300 (siEP300), and then either serum fed (Fed) or serum starved for 48 hours (SS48).
Resulting qRT-PCR expression values were normalized to control (Fed cells transfected with siNeg). * = significantly (p,0.05) different from control.
** = significantly (p,0.05) different from control and from siNeg time-matched controls. B. A404 cells were transfected with either scrambled
negative control siRNA (siNeg) or with a transcript targeting Ep300 (siEp300), and then treated with retinoic acid for 24 (RA 24 h) or 48 hours (RA
48 h), or left untreated (No RA). Resulting qRT-PCR expression values were normalized to control (No RA cells, transfected with siNeg).
* = significantly (p,0.05) different from control. ** = significantly (p,0.05) different from control and from siNeg time-matched controls.
doi:10.1371/journal.pone.0014301.g010
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SMC differentiation-specific genes.
More studies are needed to further elucidate this model. For
example, CBP may substitute for p300 in supporting cell
maintenance processes during SMC differentiation. Unlike skeletal
and cardiac muscle, SMCs maintain their phenotypic plasticity.
Microenvironmental triggers must therefore exist which are
capable of dynamically altering the epigenetic environment [5].
Given its large interactome and key role in modulating chromatin
and transcription factors, p300 presents an opportune fulcrum for
regulation of SMC phenotypic modulation.
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